Oral Pharmaceutical composition comprising Synergistic nitazoxanide and mebendazole； Preparation Process； and use for treating Human parasitic diseases caused by protozoa and helminths.
The invention relates to a synergic pharmaceutical composition of mebendazole (MBDZ) with nitazoxanide (NTZX) for the treatment of human parasitosis, which significantly increases the spectrum of MBDZ against protozoa and reinforces the anthelmintic action of NTZX. Furthermore, when said pharmaceutical combination of MBDZ and NTZX is used, the same effects of the individual active substances are maintained in the systemic action of the active metabolite of NTZX, tizoxanide, and in the treatment of some systemic forms of parasitosis. In addition, the synergic pharmaceutical combination of MBDZ with NTZX achieves a larger anti-parasite spectrum, while maintaining the efficiency and safety profiles of both active substances independently. All of these effects enable the differentiation of the pharmaceutical combination from the rest of the conventional anti-parasite treatments that have more limited spectra. The invention therefore relates principally to the synergic effects of the pharmaceutical combination of MBDZ and NTZX.La solicitud se refiere a una composición farmacéutica sinérgica adaptada para ser administrable oralmente como antiparasitario, CARACTERIZADA porque comprende una cantidad terapéuticamente (en el contexto antiparasitario) de Nitazoxanida y una cantidad terapéuticamente (en el contexto antiparasitario) de Mebendazol, junto con excipientes farmacéuticamente aceptables. También se reivindica el método para su elaboración y el uso de esta composición para la formular un medicamento útil para tratar parasitosis humanas en general y, de protozoos y helmintos en particular.
